Topical Imiquimod Treatment of Lentigo Maligna

Publication

dc.contributor.author	Ventura, F
dc.contributor.author	Rocha, J
dc.contributor.author	Fernandes, JC
dc.contributor.author	Pardal, F
dc.contributor.author	Brito, C
dc.date.accessioned	2012-02-17T13:44:08Z
dc.date.available	2012-02-17T13:44:08Z
dc.date.issued	2009
dc.description.abstract	Lentigo maligna (LM) is the in situ phase of lentigo maligna melanoma, which may progress to invasive melanoma if left untreated. It mainly occurs on sun-exposed areas of elderly patients. The lesions can be large and conventional surgery can be difficult, particularly on the face. Recent reports indicate that topical imiquimod 5% cream is effective in the treatment of LM. It may be an alternative when surgery or other classical treatments are not possible in elderly patients. We describe an 80-year-old Caucasian woman with a 10-year history of a histologically verified extensive LM of the face. She was treated with imiquimod 5% cream once daily. After four months it showed complete clinical response. One year after the treatment the patient was still free from recurrence.	por
dc.identifier.citation	Case Rep Dermatol. 2009;1(1):78-81.	por
dc.identifier.uri	http://hdl.handle.net/10400.23/149
dc.language.iso	eng	por
dc.peerreviewed	yes	por
dc.publisher	Karger	por
dc.subject	Neoplasias da Pele	por
dc.subject	Lentigo	por
dc.subject	Imiquimod	por
dc.title	Topical Imiquimod Treatment of Lentigo Maligna	por
dc.type	journal article
dspace.entity.type	Publication
rcaap.rights	openAccess	por
rcaap.type	article	por

Files

Now showing 1 - 1 of 1

Now showing 1 - 1 of 1